Athira Pharma, a Phase 2/3 biotech targeting the novel HGF/MET pathway for Alzheimer's, raised $204 million by offering 12 million shares at $17, the high end of the range of $15 to $17. The company offered 2 million more shares than anticipated. At pricing, the company raised 28% more in proceeds than expected.
Athira Pharma plans to list on the Nasdaq under the symbol ATHA. Goldman Sachs, Jefferies and Stifel acted as lead managers on the deal.
